Clinical Trial Update: Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating Omacor (omega-3 fatty acids) for cardiovascular risk factors in people with HIV on HAART. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus
• Ischemic Heart Disease

Drugs mentioned

• Omacor (omega-3-acid ethyl esters)

Snippet

Sponsor: Pronova BioPharma | Conditions: Human Immunodeficiency Virus, Ischemic Heart Disease | Phase 4 | Status: COMPLETED